Conference Programs

Molecular Diagnostics
Streamlining Companion Diagnostics

Personalized Diagnostics
Getting Ready for Clinical Use

Cancer Molecular Markers
Advancing Personalized Medicine

Circulating Tumor Cells
Future of Cancer Management

Digital Pathology - NEW
Defining a New Standard

Companion Diagnostics - NEW
Strategies and Solutions to Streamline Development

Keynote Presentations

KEYNOTE PRESENTATION IN HONOR OF
Dr. Jeffrey Kant, Former Chair, Amp Economic
Affairs Committee “May You Live in
Interesting Times:” The Evolving Landscape
of CPT Coding for Molecular Testing
Roger Klein, M.D., J.D., Department of Molecular
Pathology, Cleveland Clinic Foundation

Investing in Molecular Diagnostics
Sue E. Siegel, Corporate Officer and CEO,
healthymagination, GE

Biomarkers in Circulating Tumor Cells:
Current Progress toward Qualifying
Molecular Assays
Daniel Danila, M.D., Genitourinary Oncology
Service, Department of Medicine, Memorial Sloan-
Kettering Cancer Center

Chip-Based Characterization of the
Molecular Characteristics of CTCs in
Prostate and Lung Cancer
Daniel Haber, M.D., Ph.D., Director, Massachusetts
General Hospital Cancer Center; Isselbacher/
Schwartz Professor of Oncology, Harvard
Medical School; Investigator, Howard Hughes
Medical Institute

Circulating Tumor Cells:
Challenges and Perspectives
Klaus Pantel, M.D., Director, Institute
of Tumor Biology, UKE

Premier Sponsors:

[Elsevier, Luminex, Remedy Informatics, Singulex]
Plenary Keynotes

Wednesday, February 13 8:00 – 9:40 am

Personalized Oncology – Fulfilling the Promise for Today’s Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs. Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

Topics for discussion include:

• Scientific approaches to treating cancer, involving deep molecular profiling and pathway analysis of individual tumors to design custom treatments, and then monitoring the tumor’s response to therapy using sequential biopsies and CTCs.
• Open science initiatives to rapidly learn and refine the clinically actionable, molecular subtypes of cancer and how to treat them.
• New models of translational research that can slash the time and cost of developing highly targeted agents for rare subtypes.
• Efficient systems to enable patients affordable investigational drugs for testing in small proof-of-concept studies.
• Complementary computational approaches to identifying cancer pathways, targets, and subtypes.
• Pragmatic approaches for capturing treatment and outcomes data from every cancer patient, to validate and extend the knowledge of molecular subtypes and treatments.
• The industry ecosystem and what’s needed to deliver personalized oncology services at scale.

Moderator: Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor

Tony Blau, M.D., Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHCRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology

Sarah Greene, Executive Director, Cancer Commons

Mikhail Gishizky, Ph.D., CSO, Entelos Inc

Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation for the FDA; Former Board Chair, Lung Cancer Alliance; Cancer Survivor

Anil Sethi, CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur

Joshua Stuart, Ph.D., Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz

Thursday, February 14 8:00 – 9:40 am

Plenary Keynote Panel: Emerging Technologies & Industry Perspectives

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included.

• Moderator: To be Announced
• Gregory Parekh, Ph.D., CEO, Biocartis
• Kevin Bobofchak, Ph.D., Pathway Studio Product Manager, Elsevier
• Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation
• Panelist to be Announced, Remedy Informatics
• Harry Glorikian, Managing Partner, Scientia Advisors, LLC
• Lynn R. Zieske, Ph.D., Vice President, Commercial Solutions, Singulex, Inc.

Co-located Event

BayBio
Entrepreneur & Investor Roundtables

February 14, 2013, 4:00-7:00 pm
Connect with corporate venture, angel investors and VCs
www.baybioroundtables.com
Conference Programs:
Feb 13-15

**Diagnostics Channel**
Molecular Diagnostics
Personalized Diagnostics
Cancer Molecular Markers
Circulating Tumor Cells
Digital Pathology – NEW
Companion Diagnostics – NEW

**Therapeutics Channel**
Mastering Medicinal Chemistry
Cancer Biologics
Clinical and Translational Science

**Clinical Channel**
Oncology Clinical Trials
Clinical and Translational Science
Clinical Sequencing – NEW

**Informatics Channel**
Bioinformatics in the Genome Era
Integrated R&D Informatics and Knowledge Management

**Cancer Channel**
Cancer Molecular Markers
Circulating Tumor Cells
Predictive Pre-Clinical Models in Oncology – NEW
Oncology Clinical Trials
Cancer Biologics

Symposia*:
Feb 11-12
Targeting Cancer Stem Cells
Genomics in Medicine – NEW
Point-of-Care Diagnostics
Quantitative Real-Time PCR – NEW
Next Generation Pathology

Partnering Forum*:
Feb 11-12
Emerging Molecular Diagnostics

Short Courses*:
Feb 12
1:30-4:30pm
SC1 Identification & Characterization of Cancer Stem Cells
SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace
SC3 NGS Data and the Cloud
SC4 Best Practices in Personalized and Translational Medicine
SC5 Latest Advances in Molecular Pathology
SC6 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
SC7 PCR Part I: qPCR in Molecular Diagnostics
SC8 Data Visualization
SC9 Methods for Synthesis & Screening of Macrocyclic Compound Libraries
SC10 PCR Part II: Digital PCR Applications and Advances
SC11 Sample Prep and Biorepositories for Cancer Research
SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
SC13 Strategies for Companion Diagnostics Development
SC14 Patient-Derived Cancer Tissue Xenograph Models
SC15 Microfluidics Technology and Market Trends
SC16 Open Cloud & Data Science

5:00-8:00pm (Dinner)
SC10 PCR Part II: Digital PCR Applications and Advances
SC11 Sample Prep and Biorepositories for Cancer Research
SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
SC13 Strategies for Companion Diagnostics Development
SC14 Patient-Derived Cancer Tissue Xenograph Models
SC15 Microfluidics Technology and Market Trends
SC16 Open Cloud & Data Science

Recommended Programs:
Symposia
- Point-of-Care Diagnostics
- Genomics in Medicine
- Next Generation Pathology
- Quantitative Real-Time PCR

Short Courses
- Identification and Characterization of Cancer Stem Cells
- Commercialization Boot Camp
- NGS Data and the Cloud
- Latest Advances in Molecular Pathology
- Regulatory Approval of a Therapeutic and Companion Diagnostic
- Sample Prep and Biorepositories for Cancer Research
- NGS in Molecular Pathology
- Strategies for Companion Diagnostics Development
- Microfluidics Technology and Market Trends

**TRI-CON All Access Package**

Get the best 5-day value! Our All Access Packages is a convenient, cost-effective way to attend each aspect of Molecular Med TRI-CON 2013. Package includes access to 1 Symposium or Partnering Forum, 2 Short Courses and 1 Conference Program.

*Separate reg required with a la carte pricing*
2013 Sponsors

Premier Sponsors:

Corporate Sponsors:

Corporate Support Sponsors:

TriConference.com
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Keynote Session

11:00 Chairperson’s Opening Remarks

11:10 Investing in Molecular Diagnostics

Sue E. Siegel, Corporate Officer and CEO, healthymagination, GE

11:40 KEYNOTE PRESENTATION IN HONOR OF

Dr. Jeffrey Kant, Former Chair, Aamp Economic Affairs Committee “May You Live in Interesting Times:” The Evolving Landscape of CPT Coding for Molecular Testing

Roger Klein, M.D., J.D., Department of Molecular Pathology, Cleveland Clinic Foundation

Industry Update

12:10 pm DxInsights: Advancing Molecular Medicine

Kristin Pothier, Founder, DxInsights; Partner, Health Advances

End-to-End Companion Diagnostics Development

12:40 Luncheon Presentation I:

Sponsored by

Novel Multimodal cMET Panel:
Simultaneous and Quantitative Analysis of Copy Number Variation and Gene Expression in a Single Reaction

Lilly Kong, CSO, PrimeraDx

1:10 Luncheon Presentation II:

Sponsored by

A Fully Automated Molecular Diagnostics Platform for Companion Diagnostics and Personalized Medicine

Richard A. Montagna, Ph.D., Senior Vice President, Corporate Business Development, RHEONIX, Inc.

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

2:20 PANEL DISCUSSION: End-to-End Companion Diagnostics Development

Moderator: Harry Glorikian, Founder and Managing Partner, Scientia Advisors
Panelists: Jian Wang, Ph.D., President & CEO, BioFortis, Inc.
Gregory Zdechlik, COO, Eli Lilly & Co.
Richard Watts, Senior Director, Business Development Pharma, Companion Diagnostic Partnerships, QIAGEN
Jon Minken, Director, Reimbursement North America, Regional Marketing MDx NA, QIAGEN

3:35 Commercialization of Smart Consumables for in vitro Diagnostics

Ali Tinazli, Ph.D., Director, Business Development & Sales, Sony DADC

3:50 Solutions for the Outsourcing of Companion Diagnostics Development

Philip D. Cotter, Ph.D., Principal, ResearchDx

4:05 Multiplex Molecular Assays from Discovery to the Clinic on FFPE

Samples: Extraction-Free

BJ Karns, SVP, Translational Medicine, HTG Molecular Diagnostics, Inc.

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

NGS Diagnostics onto the iPAD:
Understanding the Physician Workflow

10:40 Chairperson’s Remarks

Alan Carter, Chief Business Officer, PanGenX

10:45 The Clinical Utility of T2DM and Other Genetic Risk Testing in Primary Care?

Alex Cho, M.D., MBA, Assistant Professor, Department of Medicine, General Internal Medicine, DUHS Center for Personalized Medicine, Duke University

11:15 Decision Support for Personalized Genomic Medicine

Mark S. Boguski, Ph.D., Associate Professor, Center for Biomedical Informatics, Harvard Medical School

11:45 Turn-Key and Precise Clinical Genome Interpretation

Dietrich Stephan, Ph.D., Founder & CEO, Silicon Valley Biosystems (SVBio)

12:15 pm Luncheon Presentation I: Multiplexed Molecular Testing for Rapid Diagnosis of Gastrointestinal Infections

Kimberle C. Chapin, M.D., Lifespan Academic Medical Centers and Brown Medical School

12:45 Luncheon Presentation II:
Inspection Ready - Regulatory Compliance of LDTs in Accredited Clinical Laboratories Can Be Eased By Utilizing the LIS

Megan Schmidt, Product Manager, Sunquest Information Systems

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
How Will New Molecular Diagnostic Technologies Affect Clinical Practice?

1:45 PANEL DISCUSSION
Moderator: Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide Research & Development, Clinical Research and Precision Medicine, Pfizer, Inc.
Panelists: Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation
David A. Flockhart, M.D., Ph.D., Harry and Edith Gladstein Chair in Cancer Genomics, Professor of Medicine, Genetics and Pharmacology, Director, Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine
Brian Kelly, Lead, Clinical & Applied Market Development, Ion Torrent Systems

3:15 Randox Biochip Array Technology (BAT) A Revolutionary Multiplex PCR Platform for Infectious Disease Molecular Diagnostics (MDx)
Scott McKeown, Ph.D., R&D Consultant, Export Sales, Randox Pharmaceutical Services, Randox Labs Ltd.

3:30 Partnering in Biomarker Driven Clinical Trials
Austin Tanney, Ph.D., Scientific Liaison Manager, Almac Group

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

How Academic Medical Centers are Leading Personalized Medicine Research
Co-Organized by

4:30 Chairperson’s Remarks
Edward Abrahams, President, Personalized Medicine Coalition

4:35 Clinical Implementation of Pharmacogenomic Testing on a Large Scale
David A. Flockhart, M.D., Ph.D., Harry and Edith Gladstein Chair in Cancer Genomics, Professor of Medicine, Genetics and Pharmacology; Director, Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine

5:05 Talk Title to be Announced
Evian Gordon, M.D., CEO, Brain Resource Company Limited

5:35 Pathways to Implementing Personalized Cardiovascular Medicine
Dan Roden, M.D., Assistant Vice Chancellor, Personalized Medicine, Vanderbilt University

6:05 Global Commercialization of Companion Diagnostics: Value Capture in Personalized Medicine
Joseph V. Ferrara, President, Boston Healthcare

6:35 Close of Day

FRIDAY, FEBRUARY 15
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

11:00 Chairperson’s Opening Remarks

11:10 Investing in Molecular Diagnostics
Sue E. Siegel, Corporate Officer and CEO, healthymagination, GE

11:40 KEYNOTE PRESENTATION IN HONOR OF Dr. Jeffrey Kant, Former Chair, Amp Economic Affairs Committee “May You Live in Interesting Times:” The Evolving Landscape of CPT Coding for Molecular Testing
Roger Klein, M.D., J.D., Department of Molecular Pathology, Cleveland Clinic Foundation

12:10 pm Microarray/Next-Generation Sequencing Quality Control Project
Leming Shi, Ph.D., National Center for Toxicological Research, U.S. Food and Drug Administration

12:40 Luncheon Presentation I: CDx Development-Are you ready? Key considerations for Rx/Dx Co-Development from the Dx Partner Perspective
Todd Krueger, Strategy Leader, Medical Sciences, Life Technologies

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

Getting Personalized Diagnostics Ready for Clinical Use

2:15 Chairperson’s Remarks

2:20 Implementation of Deep (Next-Gen) Sequencing in a Clinical Lab
Toumy Guettouche, Ph.D., Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Center for Genome Technology; Oncogenomics Core Facility; Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine

2:50 Quality Control Parameters and Software Tools to Enable Clinical Sequencing on High-Performance Sequencing Platforms
Shawn Levy, Faculty Investigator, HudsonAlpha Institute for Biotechnology

3:20 Rapid Whole Genome Sequencing: From DNA to Diagnosis in 50 Hours
Darrell Dinwiddie, Ph.D., Director, Lab Operations, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics

3:50 Solving the Challenges of DNA Sequencing for Molecular Diagnostics
Stefan Roever, CEO & Founder, Genia Technologies

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available)

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Real Data and Practical Challenges in Implementing NGS

10:40 Chairperson’s Remarks
German Pihan, M.D., Director, Hematopathology Lab, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School

10:45 Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imieliński, M.D., Ph.D., Pathology, Brigham and Women’s Hospital; Meyerson Lab, Broad Institute and Dana Farber Cancer Institute

11:15 Fundamental Insight: The Biology and Targeting of Cancer through the Lens of Exome Sequencing
German Pihan, M.D., Director, Hematopathology Lab, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School

11:45 Translation of the Cancer Genome
Lynda Chin, M.D., Professor & Chair, Department of Genomic Medicine, Scientific Director, Institute for Applied Cancer Science; M.G. & Lillie A. Johnson Chair for Cancer Treatment and Research, University of Texas MD Anderson Cancer Center

12:15 pm Using Advanced Analytics in Systems Biology to Discover Unknown Relationships and Non-Obvious Patterns
David Anstey, Global Head, Life Sciences, YarcData co-authored by: Amar Shan, Director, Product Marketing, YarcData

Sponsored by

Sponsored by

Sponsored by

Sponsored by
1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
Real Data and Practical Challenges in Implementing NGS

1:40 Chairperson’s Remarks
German Pihan, M.D., Director, Hematopathology Lab, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School

1:45 Computational Programs and Algorithms (Software) for Exome Sequence Analysis
Gaddy Getz, Director, Cancer Genome Computational Analysis, Broad Institute

2:15 Advances in Application of Next-Generation Sequencing to Cancer Diagnostics
Shashikant Kulkarni, M.S. (Medicine), Ph.D., FACMG, Head, Clinical Genomics; Medical Director, Cytogenomics and Molecular Pathology; Associate Professor; Pediatrics, Genetics, Pathology and Immunology, Washington University School of Medicine

2:45 Recent Insights from Next-Generation Sequencing (NGS) of Advanced Prostate Cancer
Akash Kumar, B.Chem.E, MS, M.D./Ph.D. Candidate, Genome Sciences, University of Washington

3:15 What Everyone Working in the Life Sciences Needs to Know About AIA and the Recent SCOTUS/Federal Circuit Decisions
Alan F. Feeney, Esq., Owner, Feeney Law Group

3:30 TeloTest™: A Transformative Telomere Length Assay in Personalized Medicine for Health Monitoring and Disease Interception
Calvin B. Harley, Ph.D., CSO, Telome Health, Inc.

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

Case Studies in Implementation of Genomic Medicine

4:30 Chairperson’s Remarks
Mark S. Boguski, Ph.D., Associate Professor, Center for Biomedical Informatics, Harvard Medical School

4:35 Genomics and the Personalization of Ovarian Cancer Care
David Huntsman, M.D., FRCP, FCCMG, Medical Director, Center for Translational & Applied Genomics, British Columbia Cancer Agency

5:05 Making a Definitive Diagnosis: Opportunities and Challenges Associated with Clinical Application of Whole Genome Sequencing
Elizabeth Worthey, Assistant Professor, Pediatrics & Bioinformatics Program, Human & Molecular Genetics Center, Medical College of Wisconsin

5:35 Case Study in Autism
Timothy W. Yu, M.D., Ph.D., Instructor in Pediatrics, Children’s Hospital Boston and Department of Neurology, Lurie Center for Autism, MassGeneral Hospital for Children

6:05 Sponsored Presentations (Opportunities Available)

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee

Cancer Molecular Markers
Shared session with Cancer Molecular Markers; please see page 9

10:05 Sponsored Presentations (Opportunities Available)

10:35 Coffee Break

Gene Panels in Oncology and Inherited Disorders

11:00 Talk Title to be Announced
Colin C. Pritchard, M.D., Ph.D., Assistant Professor & Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington

11:30 The Impact of Expanded Next-Generation Sequencing Panel Testing for Inherited Cardiomyopathies on Disease Diagnosis: Lessons from the First 500 Cases
Birgit H. Funke, Ph.D., FACMG, Assistant Professor of Pathology, MGH/Harvard Medical School; Director of Clinical Research and Development, Laboratory for Molecular Medicine, PCPGM

12:00 pm Exome Sequencing for Candidate Gene Discovery in Inherited Disorders
Karl Voelkerding, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Advanced Technology and Bioinformatics, ARUP Laboratories

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

Companion Diagnostics Post-Approval

1:45 PANEL DISCUSSION: Companion Diagnostics Post-Approval: Communicating Information to the Patient in a Global Environment
Moderator: Glenn A. Miller, Ph.D., Vice President and Head, Personalized Healthcare and Biomarkers, Strategy, Portfolio and Alliances, AstraZeneca Pharmaceuticals LP
Panelists: Richard E. Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer, La Jolla
Walter H. Koch, Ph.D., Vice President and Head, Global Research, Roche Molecular Diagnostics
William Pignato, Global Head, Regulatory Affairs, Novartis Institutes for BioMedical Research, Inc.

3:20 Close of Conference

Getting Ready for Clinical Use
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Keynote Session

11:00 Chairperson’s Opening Remarks

11:10 Biomarkers in Circulating Tumor Cells: Current Progress toward Qualifying Molecular Assays
Daniel Danila, M.D., Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center

11:40 Chip-Based Characterization of the Molecular Characteristics of CTCs in Prostate and Lung Cancer
Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute

12:10 pm Circulating Tumor Cells: Challenges and Perspectives
Klaus Pantel, M.D., Director, Institute of Tumor Biology, UKE

12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

Getting Personalized Diagnostics Ready for Clinical Use

2:15 Chairperson’s Remarks

2:20 Implementation of Deep (Next-Gen) Sequencing in a Clinical Lab
Toumy Guettouche, Ph.D., Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Center for Genome Technology; Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

2:50 Quality Control Parameters and Software Tools to Enable Clinical Sequencing on High-Performance Sequencing Platforms
Shawn Levy, Faculty Investigator, HudsonAlpha Institute for Biotechnology

3:20 Rapid Whole Genome Sequencing: From DNA to Diagnosis in 50 Hours
Darrell Dinwiddie, Ph.D., Director, Lab Operations, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics

3:50 Solving the Challenges of DNA Sequencing for Molecular Diagnostics
Stefan Roever, CEO & Founder, Genia Technologies

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

FFPE Samples

10:40 Chairperson’s Remarks

10:45 Deep Sequencing of DNA and RNA from FFPE Samples
Toumy Guettouche, Ph.D., University of Miami, School of Medicine

11:15 Molecular Tools for Pathology Diagnostics: Requirements in Terms of Turnaround Time, Specimens, and Quality Assurance
Daniëlle A.M. Heideman, Ph.D., Assistant Professor, Department of Pathology, Molecular Pathology Unit, VU University Medical Center

11:45 Molecular Diagnostic Tests to Augment Cytomorphologic Diagnosis of Lung Cancer
James C. Willey, M.D., Professor, Medicine and Pathology, University of Toledo College of Medicine; Consultant, Accugenomics, Inc.

12:15 pm ATCC Molecular Signature Tumor Cell Panels for Drug Screening
Philip Wang, Ph.D., Business Marketing Manager, ATCC

12:30pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
Single Cell Analyses

1:40 Chairperson’s Remarks

1:45 Single Cell Profiling of Circulating Tumor Cells
Stefanie Jeffrey, M.D., John and Marva Warnock Professor,
Department of Surgery, Chief of Surgical Oncology Research,
Stanford University School of Medicine

2:15 Microtechnologies to Interrogate Signaling in
Single Cells
Nancy Allbritton, M.D., Ph.D., Professor & Chair, UNC/NCSU
Department of Biomedical Engineering; Chair, UNC CASE;
Department of Chemistry, Department of Pharmacology,
University of North Carolina; Department of Materials Science &
Engineering, North Carolina State University

2:45 NanoVelcro-Embedded Microchips for
Detection and Isolation of Circulating Tumor Cells: Validation Studies in Oncology Clinic
Hsian-Rong Tseng, Ph.D., Associate Professor, Department of
Molecular and Medical Pharmacology, Crump Institute for
Molecular Imaging, Institute for Molecular Medicine, University of
California, Los Angeles; California NanoSystems Institute

3:15 Molecular Analyses of
Circulating Tumor Cells: Which View for their Use to Improve
Follow Up and Treatment of Patients with Cancer?
Patrizia Paterlini-Brechot, Professor, Cell Biology & Oncology,
University Paris Descartes, Paris; Director, INSERM Unit 807 &
CSO, Rarecells

3:45 Valentine’s Day Celebration and Poster
Competition Winner Announced in the Exhibit Hall
(Last Chance for Poster Viewing)

4:35 The Ephesia Magnetic Arrays Technology,
towards Quantitative High Content CTC Screening
Jean-Louis Vivoy, Research Director, Macromolecules and Microsystems in Biology and Medicine Lab, Institute Curie

5:05 Digital Profiling of Circulating Tumor Cells:
Towards Point-of-Care Molecular Diagnostics
Balaji Panchapakesan (Baloo), Ph.D., Associate Professor of
Mechanical Engineering, University of Louisville

5:35 Single-Cell Digital Gene
Expression of 800 mRNA
Targets: Applications for Circulating Tumor Cells
Joseph M. Beechem, Ph.D., Senior Vice President, Research &
Development, NanoString Technologies

6:05 Advanced Platform for Real-Time Monitoring
of Circulating Tumor Cells Beyond the
Detection Limits
Vladimir Zharov, Ph.D., D.Sc., Professor, Director, Arkansas
Nanomedicine Center, University of Arkansas for
Medical Sciences

6:35 Close of Day
Third Annual Circulating Tumor Cells

WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Keynote Session

11:00 Chairperson's Opening Remarks

11:10 Biomarkers in Circulating Tumor Cells: Current Progress toward Qualifying Molecular Assays
Daniel Danila, M.D., Genitourinary Oncology Service, Medicine, Memorial Sloan-Kettering Cancer Center

11:40 Chip-Based Characterization of the Molecular Characteristics of CTCs in Prostate and Lung Cancer
Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute

12:10 pm Circulating Tumor Cells: Challenges and Perspectives
Klaus Pantel, M.D., Director, Institute of Tumor Biology, UKE

12:40 Characterization of Circulating Tumor Cells With the CellSearch Platform
Brad Foulk, Senior Scientist, Janssen R&D

1:10 Luncheon Presentation II: Maximizing Clinical Utility of Non-Invasive Biomarkers
Anthony P. Shuber, CTO, Predictive Biosciences

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

Liquid Biopsy

2:15 Chairperson's Remarks

2:20 Circulating Tumor Cells: Current Clinical Utility and Future Directions
Daniel Hayes, M.D., Professor, Internal Medicine, University of Michigan, Ann Arbor

2:50 Sequencing and Monitoring Circulating Free DNA in Colorectal Cancer Patients
Luis Diaz, M.D., Associate Professor of Oncology, Director of Translational Medicine, Ludwig Center at Johns Hopkins, Kimmel Cancer Center, Johns Hopkins

3:20 Digital Profiling of Circulating Tumor Cells: Towards Point-of-Care Molecular Diagnostics
Balaji Panchapakesan (Baloo), Ph.D., Associate Professor of Mechanical Engineering, University of Louisville

3:50 The Capture, Growth and Genetic Analysis of CTC in PDAC: What Can it Tell Us About this Disease?
Sarah P. Thayer, M.D., Ph.D., Associate Professor, Surgery, W. Gerald Austen Scholar in Academic Surgery & Director, Pancreatic Biology Laboratory, Massachusetts General Hospital

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

CTCs in Companion Diagnostics

10:40 Chairperson's Remarks

10:45 Capturing and Molecular Analysis of Circulating Tumor Cells to Support Early Clinical Studies
Thomas Krahn, Ph.D., Head, Global Biomarker Research, Bayer Healthcare Pharmaceuticals, Bayer Pharma AG

11:15 Implementation of CTC Assays in Oncology Clinical Trials
Iman Jilani, Ph.D., Associate Director, Clinical Assay Group, Global Clinical Pharmacology, Pfizer, Inc.

11:45 Analysis and Characterization of Subpopulations of Circulating Tumor Cells in Breast Cancer Patients
Haifeng Bao, Principal Scientist, Research & Development Translational Sciences, MedImmune

12:15 pm Assessment of Single Cell Mutational Status Reveals Breast Cancer CTC Heterogeneity
Nicolo Manaresi, Ph.D., CTO, Silicon Biosystems

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Single Cell Analyses

1:40 Chairperson’s Remarks

1:45 Single Cell Profiling of Circulating Tumor Cells
Stefanie Jeffrey, M.D., John and Marva Warnock Professor, Surgery, Chief of Surgical Oncology Research, Stanford University School of Medicine

2:15 Microtechnologies to Interrogate Signaling in...
Single Cells
Nancy Allbritton, M.D., Ph.D., Professor & Chair, UNC/NCSU Biomedical Engineering; Chair, UNC CASE; Chemistry, Pharmacology, University of North Carolina; Materials Science & Engineering, North Carolina State University

2:45 NanoVelcro-Embedded Microchips for Detection and Isolation of Circulating Tumor Cells: Validation Studies in Oncology Clinic
Hsian-Rong Tseng, Ph.D., Associate Professor, Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Institute for Molecular Medicine, University of California, Los Angeles; California NanoSystems Institute

3:15 Molecular Analyses of Circulating Tumor Cells: Which View for their Use to Improve Follow Up and Treatment of Patients with Cancer?
Patrizia Paterlini-Brechot, Professor, Cell Biology & Oncology, University Paris Descartes, Paris; Director, INSERM Unit 807 & CSO, Rarecells

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

4:35 The Ephesia Magnetic Arrays Technology, towards Quantitative High Content CTC Screening
Jean-Louis Viovy, Research Director, Macromolecules and Microsystems in Biology and Medicine Lab, Institute Curie

5:05 Expanding the Definition of Traditional CTCs: Cells Associated with Cancer in the Blood of Patients with Solid Tumors
Jeffrey J. Chalmers, Ph.D., Professor, Chemical & Biomolecular Engineering; Director, Analytical Cytometry Shared Resource, The Ohio State University Comprehensive Cancer Center

5:35 Single-Cell Digital Gene Expression of 800 mRNA Targets: Applications for Circulating Tumor Cells
Joseph M. Beechem, Ph.D., Senior Vice President, Research & Development, NanoString Technologies

6:05 Advanced Platform for Real-Time Monitoring of Circulating Tumor Cells Beyond the Detection Limits
Vladimir Zharov, Ph.D., D.Sc., Professor, Director, Arkansas Nanomedicine Center, University of Arkansas for Medical Sciences

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee
Detection Systems

8:30 Chairperson’s Remarks
Lynn Sorbara, Ph.D., Program Director, NIH/NCI/Division of Cancer Prevention, Cancer Biomarker Research Group

8:35 Application of iCTC Detection and Culture in Personalized Cancer Management
Wen-Tien Chen, Ph.D., Research Professor, Gynecologic Oncology, Stony Brook University Medical Center

9:05 Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis
David A. Lawrence, Ph.D., Chief, Laboratory of Immunology, Wadsworth Center, NYSDOH

9:35 Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles
Shan X. Wang, Ph.D., Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine), Director, Stanford Center for Magnetic Nanotechnology

10:05 Nonfluorescent Microfilter with Uniform Pore Distribution to Isolate and Analyze CTCs
Cha-Mei Tang, Sc.D., President & CEO, Creatv MicroTech, Inc.

10:35 Coffee Break
Capture Technology Improvements

10:55 Chairperson’s Remarks
Steven A. Soper, Ph.D., Professor, Biomedical Engineering; Professor, Chemistry; Director, CBMM; Pyor Emeritus Professor (LSU), University of North Carolina, Chapel Hill

11:00 Photoacoustic Detection and Capture of CTCs
Martin E. Sanders, M.D., Executive Chairman, Viator Technologies, Inc.

11:30 The Fluid Phase of Solid Tumors: How Does Cancer Spread?
Peter Kuhn, Ph.D., Associate Processor, Cell Biology, The Scripps Research Institute

12:00 pm Utilization of Dielectrophoresis for Antigen Independent Circulating Tumor Cell (CTC) Capture Allows for Detection of Heterogeneous Tumor Cell Populations
Andrew Poklepovic, M.D., Assistant Professor, Internal Medicine, Virginia Commonwealth University

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

Is the Clinical Need for CTCs Evolving?

1:50 PANEL DISCUSSION
Moderator: Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute
Panelists: Daniel Hayes, M.D., Professor, Internal Medicine, University of Michigan, Ann Arbor
Luis Diaz, M.D., Associate Professor of Oncology, Director of Translational Medicine, Ludwig Center at Johns Hopkins, Kimmel Cancer Center at Johns Hopkins
Lyndsay N. Harris, M.D., Case Comprehensive Cancer Center, Case Western Reserve

3:20 Close of Conference

Future of Cancer Management
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Introduction

11:00 Chairperson’s Opening Remarks

11:10 Digital Pathology: The Big Picture
Liron Pantanowitz, M.D., Associate Professor of Pathology, University of Pittsburgh Medical Center; Department of Pathology, UPMC Shadyside

Image Analysis & Advanced Imaging

11:40 Workflow Management: From Imaging to Analysis and Database Curation
BS Manjunath, Director, Center for Bio-image Informatics; Vice Chair and Undergraduate Program Director, Department of Electrical and Computer Engineering, University of California Santa Barbara

12:10 pm Multiplexed Imaging, Pathology and Personalized Medicine: Keeping Sight of the Forest
Richard Levenson, M.D., Professor and Vice Chair for Strategic Technologies, Department of Pathology & Laboratory Medicine, University of California Davis Medical Center

12:40 Luncheon Presentation I: Genetically Engineered Miniature Swine Models of Cancer: Bridging the Pre-Clinical Gap from Rodents to Humans
John Swart, Ph.D., President, Exemplar Genetics

1:10 Luncheon Presentation II: (Sponsorship Opportunity Available) or Lunch on Your Own

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

2:20 Ephemeral Images, Indelible Data: The Promises and Challenges of Digital Imaging as Applied to Pathology
Ulysses Balis, M.D., Ph.D., Associate Professor, Pathology, University of Michigan

2:50 Filling the Training Gap for Future Pathologists: How Does a Novice like Me Catch Up?
Lewis A. Hassell, M.D., Department of Pathology, University of Oklahoma College of Medicine

3:20 Q&A with Speakers

3:50 Accelerating and Advancing Dx and CDx Biomarker Development from Discovery to Clinical Trials by Seemlessly Integrating Image Analysis with Data Mining
Alan Jerusalmi, Ph.D., Director, Professional Services, Definiens

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Image Analysis & Advanced Imaging

10:40 Chairperson’s Remarks

10:45 Breast Cancer Predictive Factor Testing: The Challenge and Importance of Standardizing Pre-Analytic Variables
David G. Hicks, M.D., FCAP, Professor and Director, Surgical Pathology Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center

11:15 Quantitative in situ Measurement of Biomolecules for Companion Diagnostics
David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University

11:45 Advanced Optical Imaging Tools for Pathologists
Sushmita Mukherjee, Ph.D., M.S., Assistant Professor, Biochemistry, Director, Multiphoton Microscopy Facility, Weill Medical College of Cornell University

12:15 Assay-Ready Tumor Cell Panels in Cancer Biology and Drug Discovery
Jeffrey Hung, Ph.D., Chief Marketing Officer, ATCC

12:50 Accelerating and Advancing Dx and CDx Biomarker Development from Discovery to Clinical Trials by Seemlessly Integrating Image Analysis with Data Mining
Alan Jerusalmi, Ph.D., Director, Professional Services, Definiens

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day
2:45 Q&A with Speakers

3:15 DNA as Storage Platform: An Overview
Sponsored by EMC® ISILON
Sanjay Joshi, CTO, Life Sciences, Isilon Storage Division, EMC Corporation

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

4:00 Chairperson’s Remarks

4:05 Practical ePathology Solutions for Community Pathologists: What a Difference a Letter Makes
Eric F. Glassy, M.D., Medical Director, Pathology, Inc.

5:05 Developing Infrastructure which Enables the Insourcing of Telepathology Consultation into a Subspecialty Practice
David C. Wilbur, M.D., Professor, Pathology, Harvard Medical School and Massachusetts General Hospital

5:35 Digital Pathology with China: Waking the Sleeping Giant
Jian Yu Rao, M.D., Professor, Pathology and Laboratory Medicine, UCLA Program on Genomics and Nutrition

6:05 Sponsored Presentations (Opportunities Available)

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee

8:30 Chairperson’s Remarks

8:35 Telepathology Initiative for Improved Patient Care in VISN 8 Veteran’s Administration Network
Sara N. Grimsgaard, MHMS, Telepathology Specialist, Pathology & Laboratory Medicine Service, James A. Haley Veterans Medical Center

9:05 A Systems Approach: Integrating Molecular and other Novel Diagnostics into Comprehensive Pathology Consultations
Sylvia L. Asa, M.D., Ph.D., Medical Director, Laboratory Medicine Program, University Health Network and Lakeridge Health; Senior Scientist, Ontario Cancer Institute; Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto

9:35 A Better View Ahead: Next Generation Approaches to Cellular Analysis
Kenneth J. Bloom, M.D., CMO, Clarient, Inc.

10:05 Sponsored Presentations (Opportunities Available)

10:35 Coffee Break

11:00 Essential Digital Pathology: Perfecting Digital Image Acquisition
Yukako Yagi, Ph.D., MGH Pathology Imaging & Communication Technology (PICT) Center, Massachusetts General Hospital; Wellman Center for Photomedicine, Massachusetts General Hospital; Pathology, Harvard Medical School

11:30 Real-Time Deformable Registration of Multi-Modal Whole Slides for Digital Pathology
Dirk Vossen, Ph.D., Director, Applications and Q&R, Philips Digital Pathology

12:00 pm How Do You Make Sure WSI are Safe to Use?
Elizabeth A. Krupinski, Ph.D., Professor & Vice Chair, Research, Department of Medical Imaging, University of Arizona

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 Chairperson’s Remarks

1:50 Validation of Digital Whole Slide Images (WSI) for Diagnosis and Correlation Studies
Anil V. Parwani, M.D., Ph.D., Director, Division of Pathology Informatics, University of Pittsburgh

2:20 Regulatory Issues & the Practice of Digital Pathology
Keith Kaplan, M.D., Pathologist and CIO, Carolinas Pathology Group

2:50 Wrap-Up
Liron Pantanowitz, M.D., Associate Professor of Pathology, University of Pittsburgh Medical Center; Department of Pathology, UPMC Shadyside

3:20 Close of Conference
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (Details on page 2)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Keynote Session

11:00 Chairperson’s Opening Remarks

11:10 Investing in Molecular Diagnostics
Sue E. Siegel, Corporate Officer and CEO, healthymagination, GE

11:40 KEYNOTE PRESENTATION IN HONOR OF
Dr. Jeffrey Kant, Former Chair, Amp Economic Affairs Committee “May You Live in Interesting Times:” The Evolving Landscape of CPT Coding for Molecular Testing
Roger Klein, M.D., J.D., Department of Molecular Pathology, Cleveland Clinic Foundation

Industry Update

12:10 pm DxInsights: Advancing Molecular Medicine
Kristin Pothier, Founder, DxInsights; Partner, Health Advances

End-to-End Companion Diagnostics Development

12:40 Luncheon Presentation I: Novel Multimodal cMET Panel: Simultaneous and Quantitative Analysis of Copy Number Variation and Gene Expression in a Single Reaction
Lilly Kong, CSO, PrimeraDx

1:10 Luncheon Presentation II: A Fully Automated Molecular Diagnostics Platform for Companion Diagnostics and Personalized Medicine
Richard A. Montagna, Ph.D., Senior Vice President, Corporate Business Development, RHEONIX, Inc.

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

2:20 PANEL DISCUSSION: End-to-End Companion Diagnostics Development
Moderator: Harry Glorikian, Founder and Managing Partner, Scientia Advisors
Panelists: Jian Wang, Ph.D., President & CEO, BioFortis, Inc. Gregory Zdechlik, COO, Eli Lilly & Co.
Richard Watts, Senior Director, Business Development Pharma, Companion Diagnostic Partnerships, QIAGEN
Jon Minken, Director, Reimbursement North America, Regional Marketing MDx NA, QIAGEN

3:35 Commercialization of Smart Consumables for in vitro Diagnostics
Ali Tinazli, Ph.D., Director, Business Development & Sales, Sony DADC

3:50 Solutions for the Outsourcing of Companion Diagnostics Development
Philip D. Cotter, Ph.D., Principal, ResearchDx

4:05 Multiplex Molecular Assays from Discovery to the Clinic on FFPE Samples: Extraction-Free Speaker to be Announced

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

CTCs In Companion Diagnostics

10:40 Chairperson’s Remarks

10:45 Capturing and Molecular Analysis of Circulating Tumor Cells to Support Early Clinical Studies
Thomas Krahn, Ph.D., Head, Global Biomarker Research, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG

11:15 Implementation of CTC Assays in Oncology Clinical Trials
Iman Jilani, Ph.D., Associate Director, Clinical Assay Group, Global Clinical Pharmacology, Pfizer, Inc.

11:45 Analysis and Characterization of Subpopulations of Circulating Tumor Cells in Breast Cancer Patients
Haifeng Bao, Principal Scientist, Research & Development Translational Sciences, MedImmune

12:15 pm Assessment of Single Cell Mutational Status Reveals Breast Cancer CTC Heterogeneity
Nicolo Manaresi, Ph.D., CTO, Silicon Biosystems
12:30 pm Luncheon Presentation: High Density Protein Microarray and its Application in Developing Ultra-Specific mAbs
Weiwwu He, Ph.D., CEO & President, OriGene Technologies, Inc

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

How Will New Molecular Diagnostic Technologies Affect Clinical Practice?

1:45 PANEL DISCUSSION
Moderator: Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide Research & Development, Clinical Research and Precision Medicine, Pfizer, Inc.
Panelist: Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation
Additional Panelists to be Announced

3:15 Molecular Diagnostic Assays Multiplexed with Randox Biochip Array Technology
Scott McKeown, Ph.D., R&D Consultant, Randox Pharmaceutical Services, Randox Labs Ltd.

3:30 Partnering in Biomarker Driven Clinical Trials
Austin Tanney, Ph.D., Scientific Liaison Manager, Almac Group

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

How Academic Medical Centers are Leading Personalized Medicine Research
Co-Organized by

4:30 Chairperson’s Remarks
Edward Abrahams, President, Personalized Medicine Coalition

4:35 Clinical Implementation of Pharmacogenomic Testing on a Large Scale
David A. Fluckhart, M.D., Ph.D., Harry and Edith Gladstein Chair in Cancer Genomics, Professor of Medicine, Genetics and Pharmacology, Director, Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine

5:05 Talk Title to be Announced
Evian Gordon, M.D., CEO, Brain Resource Company Limited

5:35 Pathways to Implementing Personalized Cardiovascular Medicine
Dan Roden, M.D., Assistant Vice Chancellor of Personalized Medicine, Vanderbilt University

6:05 Global Commercialization of Companion Diagnostics: Value Capture in Personalized Medicine
Joseph V. Ferrara, President, Boston Healthcare

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee

8:30 Chairperson’s Remarks

8:35 Successful Development and Commercialization of Precision Medicines: “It Takes a Village”
Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide R&D, Clinical Research and Precision Medicine, Pfizer

9:05 Emerging Regulatory Trends in Drug-Diagnostic Co-Development
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.

9:35 From Biomarker to Companion Diagnostics: The Process Starts Early
Premal Shah, Ph.D., Director, Business Development, Genomic Health, Inc. (tentative)

10:05 Sponsored Presentations (Opportunities Available)

10:35 Coffee Break

Cost/Benefit Analysis of Companion Diagnostics

11:00 PANEL DISCUSSION
Economic factors driving pharma’s decision-making regarding the companion diagnostic route, as well as the perspectives of the payer and regulator.
Moderator: Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Life Science & Government Strategy & Medical Coverage & Reimbursement, Foley Hoag
Emily S. Reese, MPH, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy
Larry J. Lesko, Ph.D., FCP, Professor, Department of Pharmaceutics, University of Florida College of Pharmacy

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

Companion Diagnostics Post-Approval

1:45 PANEL DISCUSSION: Companion Diagnostics Post-Approval: Communicating Information to the Patient in a Global Environment
Moderator: Glenn A. Miller, Ph.D., Vice President and Head, Personalized Healthcare and Biomarkers, Strategy, Portfolio and Alliances, AstraZeneca Pharmaceuticals LP
Panelists: Richard E. Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer, La Jolla
Walter H. Koch, Ph.D., Vice President and Head, Global Research, Roche Molecular Diagnostics
William Pignato, Global Head, Regulatory Affairs, Novartis Institutes for BioMedical Research, Inc.

3:20 Close of Conference
Hotel Information

Reserve your hotel and save $100 off your conference registration*

*You must book your reservation under the Tri-Conference room block for a minimum of 4 nights at the Marriott or the Intercontinental Hotel. One discount per hotel room.

Conference Venue:
The Moscone North Convention Center
747 Howard Street
San Francisco, CA 94103
www.moscone.com

Host Hotel:
San Francisco Marriott Marquis
55 Fourth Street
San Francisco, CA 94103
(T) 415-896-1600
Reservations: 888-575-8934
Discounted Group Rate: $229 s/d*
Cutoff Date: January 14, 2013
* Room Rate includes complimentary internet access in your guestroom

Additional Recommended Hotel:
InterContinental San Francisco Hotel
888 Howard Street
San Francisco, CA 94103
(T) 415-616-6500
Discounted Group Rate: $235 s/d
Cut Off Date: January 14, 2013

Please visit TriConference.com to make your reservations online or call the hotel directly to reserve your sleeping accommodations. You will need to identify yourself as a Molecular Med Tri-Con attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.

Sponsorship & Exhibit Opportunities

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post-show delegate lists. Signing on early will allow you to maximize exposure to hard-to-reach decision makers.

Breakfast & Luncheon Presentations
Opportunities may include a 15 or 30-minute podium presentation during the main agenda. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. Packages include: exhibit space, on-site branding, and more.

Invitation-Only VIP Dinner/Private Receptions
Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor's objectives.

Exhibit
Exhibitors will enjoy facilitated networking opportunities with 3,000 highly-targeted delegates at the overall event. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Inquire about additional branding opportunities, including our Valentine's Day Soiree Sponsorship!

Looking for additional ways to drive leads to your sales team? CHI can help!
We offer clients numerous options for custom lead generation programs to address their marketing and sales needs, including:

- Live Webinars
- White Papers
- Market Surveys
- Podcasts and More!

For sponsorship & exhibit information, please contact:

Companies A-K
Jon Stroup, Manager, Business Development
781-972-5483 • jstroup@healthtech.com

Companies L-Z
Joseph Vacca, Manager, Business Development
781-972-5431 • jvacca@healthtech.com
How to Register: TriConference.com/Diagnostics
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use 
keycode DXX F 
when registering!